We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




T Cell Antibody and Memory in H7N9 Survivors Characterized

By LabMedica International staff writers
Posted on 19 Jul 2019
Print article
Image: A scanning electron micrograph (SEM) of infectious particles of the avian H7N9 virus emerging from a cell (Photo courtesy of Medical Xpress).
Image: A scanning electron micrograph (SEM) of infectious particles of the avian H7N9 virus emerging from a cell (Photo courtesy of Medical Xpress).
Avian influenza A (H7N9) is a subtype of influenza viruses that have been detected in birds in the past. This particular A (H7N9) virus had not previously been seen in either animals or people until it was found in March 2013 in China.

However, since then, infections in both humans and birds have been observed. The disease is of concern because most patients have become severely ill. Most of the cases of human infection with this avian H7N9 virus have reported recent exposure to live poultry or potentially contaminated environments, especially markets where live birds have been sold.

Scientists from the Beijing Institute of Microbiology and Epidemiology (Beijing, China) and their colleagues recently sought to understand why despite the importance of immunological memory for protective immunity against viral infection, whether H7N9-specific antibodies and memory T-cell responses remain detectable years after initial infection. The team conducted across-sectional study to investigate the immune memory responses of H7N9 patients who contracted the disease and survived during the 2013–2016 epidemics in China. Sustainability of antibodies and T-cell memory to H7N9 virus were examined. Healthy subjects receiving routine medical examination in physical examination center were recruited as control.

A total of 75 survivors were enrolled and classified into four groups based on the time elapsed from illness onset to specimen collection: three months (n=14), 14 months (n=14), 26 months (n=28), and 36 months (n=19). Approximately 36 months after infection, the geometric mean titers of virus-specific antibodies were significantly lower than titers in patients of three months after infection, but 16 of 19 (84.2%) survivors in the 36-month interval had microneutralization (MN) titer > 40. Despite the overall declining trend, the percentages of virus-specific cytokines-secreting memory CD4+ and CD8+ T-cells remained higher in survivors at nearly all time points in comparison with control subjects.

Linear regression analysis showed that severe disease (mean titer ratio 2.77) was associated with higher hemagglutination inhibition (HI) titer, and female sex for both HI (1.92) and MN (3.33) antibody, whereas female sex (mean percentage ratio 1.69), underlying medical conditions (1.94) and lack of antiviral therapy (2.08) were predictors for higher T-cell responses.

The authors concluded that survivors from H7N9 virus infection produced long-term antibodies and memory T-cells responses. The study was published on June 20, 2019, in the journal Clinical Microbiology and Infection.

Related Links:
Beijing Institute of Microbiology and Epidemiology

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
High Performance Centrifuge
CO336/336R
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.